At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
IPX066 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa
In Brief
A Phase 2 clinical trial evaluating IPX066 and IR CD-LD for Parkinson's Disease. Completed, enrolled 27 participants across 1 site.
Detailed Summary
This study evaluated the pharmacokinetics, motor effects, and assessed the safety of IPX066 compared with an immediate-release cabridopa-levodopa formulation in subjects with advanced Parkinson's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedMar 2009
Primary CompletionJun 2009
TodayJul 2026
First PostedMar 26, 2009
Enrollment StartNov 1, 2008
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.3 years ago
Interventions
IPX066drug
experimental drug product: extended-release carbidopa-levodopa capsules
IR CD-LDdrug
active comparator: immediate-release carbidopa-levodopa capsules